Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Who May Qualify: - Age ≥18 years at the time of signing the ICF. - Provision of a signed and dated written ICF. - Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology. - Adequate organ and bone marrow function. - At least 1 measurable not previously irradiated lesion per RECIST 1.1 - expected to live at least 12 weeks at the time of screening. - Willing and able to provide an adequate tumor sample. Who Should NOT Join This Trial: - History of allogeneic organ transplantation. - Active or prior documented autoimmune or inflammatory disorders. - Uncontrolled intercurrent illness. - History of another primary malignancy, leptomeningeal carcinomatosis, and active primary weakened immune system. - Active infection, brain metastases or spinal cord compression. - Participants co-infected with HBV and hepatitis D virus (HDV). - Previous treatment in the present study. - For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation. Always talk to your doctor about whether this trial is right for you.